Jeffrey Skinner

420 total citations
16 papers, 220 citations indexed

About

Jeffrey Skinner is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Jeffrey Skinner has authored 16 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 12 papers in Genetics and 7 papers in Rheumatology. Recurrent topics in Jeffrey Skinner's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Eosinophilic Disorders and Syndromes (7 papers). Jeffrey Skinner is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Eosinophilic Disorders and Syndromes (7 papers). Jeffrey Skinner collaborates with scholars based in United States. Jeffrey Skinner's co-authors include Elias Jabbour, Hagop M. Kantarjian, Gautam Borthakur, Naveen Pemmaraju, Alessandra Ferrajoli, Yesid Alvarado, Musa Yılmaz, Jörge E. Cortes, Koichi Takahashi and Zeev Estrov and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jeffrey Skinner

14 papers receiving 217 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Skinner United States 6 188 162 94 40 24 16 220
Lauren T. Adrian United States 6 158 0.8× 123 0.8× 81 0.9× 28 0.7× 40 1.7× 9 202
Carla Boquimpani Brazil 9 231 1.2× 199 1.2× 108 1.1× 60 1.5× 10 0.4× 29 241
Vasily Shuvaev Russia 8 232 1.2× 211 1.3× 104 1.1× 54 1.4× 40 1.7× 54 255
Fabian Lang Germany 8 227 1.2× 164 1.0× 69 0.7× 53 1.3× 67 2.8× 39 285
Daniela Žáčková Czechia 8 140 0.7× 109 0.7× 45 0.5× 40 1.0× 25 1.0× 34 175
Kristina Myhr‐Eriksson Sweden 7 160 0.9× 95 0.6× 45 0.5× 32 0.8× 47 2.0× 7 180
Shanti Amé France 8 168 0.9× 115 0.7× 53 0.6× 39 1.0× 32 1.3× 17 207
G. J. Ossenkoppele Netherlands 10 263 1.4× 206 1.3× 134 1.4× 27 0.7× 25 1.0× 17 279
Sa-Hee Park South Korea 6 127 0.7× 100 0.6× 63 0.7× 17 0.4× 18 0.8× 9 155
Franck E. Nicolini France 3 180 1.0× 160 1.0× 117 1.2× 15 0.4× 11 0.5× 6 190

Countries citing papers authored by Jeffrey Skinner

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Skinner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Skinner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Skinner more than expected).

Fields of papers citing papers by Jeffrey Skinner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Skinner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Skinner. The network helps show where Jeffrey Skinner may publish in the future.

Co-authorship network of co-authors of Jeffrey Skinner

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Skinner. A scholar is included among the top collaborators of Jeffrey Skinner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Skinner. Jeffrey Skinner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Jabbour, Elias, Fadi Haddad, Koji Sasaki, et al.. (2024). Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 130(15). 2652–2659. 8 indexed citations
2.
Haddad, Fadi, Koji Sasaki, Ghayas C. Issa, et al.. (2023). Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clinical Lymphoma Myeloma & Leukemia. 23(10). 742–748. 13 indexed citations
3.
Haddad, Fadi, Koji Sasaki, Ghayas C. Issa, et al.. (2022). More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. Blood. 140(Supplement 1). 3897–3899. 2 indexed citations
4.
Bataller, Álex, Koji Sasaki, Elias Jabbour, et al.. (2022). Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia. Blood. 140(Supplement 1). 3895–3896. 1 indexed citations
5.
Jabbour, Elias, Koji Sasaki, Fadi Haddad, et al.. (2022). Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. American Journal of Hematology. 97(11). 1413–1418. 25 indexed citations
6.
Jabbour, Elias, Koji Sasaki, Ghayas C. Issa, et al.. (2022). Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood. 140(Supplement 1). 809–811.
7.
Haddad, Fadi, Koji Sasaki, Ghayas C. Issa, et al.. (2022). Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood. 140(Supplement 1). 1493–1494. 5 indexed citations
8.
Maiti, Abhishek, Jörge E. Cortes, Keyur P. Patel, et al.. (2020). Long‐term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 126(7). 1502–1511. 24 indexed citations
9.
Sasaki, Koji, Elias Jabbour, Ghayas C. Issa, et al.. (2020). Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood. 136(Supplement 1). 25–26. 4 indexed citations
10.
Sasaki, Koji, Hagop M. Kantarjian, Ghayas C. Issa, et al.. (2020). Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. Blood. 136(Supplement 1). 42–44. 3 indexed citations
11.
Naqvi, Kiran, Elias Jabbour, Jeffrey Skinner, et al.. (2019). Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer. 126(1). 67–75. 80 indexed citations
12.
Naqvi, Kiran, Elias Jabbour, Jeffrey Skinner, et al.. (2018). Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer. 124(13). 2740–2747. 49 indexed citations
13.
Naqvi, Kiran, Jörge E. Cortes, Jeffrey Skinner, et al.. (2017). Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Blood. 130. 1611–1611. 1 indexed citations
14.
Naqvi, Kiran, Jörge E. Cortes, Jeffrey Skinner, et al.. (2017). Early results of lower-dose dasatinib, 50 mg daily, in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.. Journal of Clinical Oncology. 35(15_suppl). e18551–e18551.
15.
Sasaki, Koji, Hagop M. Kantarjian, Elias Jabbour, et al.. (2016). Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood. 128(22). 940–940. 4 indexed citations
16.
Maiti, Abhishek, Hagop M. Kantarjian, Keyur P. Patel, et al.. (2016). Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).. Journal of Clinical Oncology. 34(15_suppl). e18542–e18542. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lauren T. Adrian Breakdown of academic impact, for papers by Carla Boquimpani Breakdown of academic impact, for papers by Vasily Shuvaev Breakdown of academic impact, for papers by Fabian Lang Breakdown of academic impact, for papers by Daniela Žáčková Breakdown of academic impact, for papers by Kristina Myhr‐Eriksson Breakdown of academic impact, for papers by Shanti Amé Breakdown of academic impact, for papers by G. J. Ossenkoppele Breakdown of academic impact, for papers by Sa-Hee Park Breakdown of academic impact, for papers by Franck E. Nicolini
Rankless by CCL
2026